Treatment and Outcome of Children With Neuroblastoma in India: Report From the InPOG‐NB‐18‐01 India Neuroblastoma Registration Study
Pediatric Blood & Cancer · 2026
DOI: 10.1002/1545-5017.70431 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Pediatric Blood & Cancer, 2026. Verfasst von Jyothi Muni Reddy und 15 weiteren Autor:innen. Beteiligte Einrichtung: St. John's Medical College Hospital, Bengaluru, India. Hauptthemen laut MEDLINE: Neuroblastoma, Registries, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Aim
To describe the clinical, management, and outcome profile of childhood neuroblastoma (NB) in India and identify barriers to optimal management.
Methods
Retrospective (InPOG‐NB‐18‐01) analysis of NB in children under 15 diagnosed between June 2016 and August 2021 across 14 centers, with prospective follow‐up for survival outcomes.
Results
A total of 320 children with NB were included, with a median age of 29 months (interquartile range [IQR]: 14–55 months) and a male:female ratio of 1.36:1. Nuclear imaging for staging and MYCN amplification testing were performed in 60.3% and 72.5% of cases, respectively. International Neuroblastoma Risk Group (INRG) staging was L1, L2, M, and MS in 39 (12.2%), 89 (27.8%), 175 (54.7%), and 17 (5.3%), respectively. The INRG risk groups were Very low risk, Low risk, Intermediate risk, and High risk in 48 (15%), 29 (9%), 47 (14.7%), and 168 (52.5%) children, respectively, with 28 (8.8%) unknown due to diagnostic limitations. Over half of patients had high‐risk neuroblastoma (HR‐NB), and of those, only 55 (32.4%) underwent high‐dose chemotherapy with autologous stem cell rescue (HDCT/ASCR), and one (0.6%) received anti‐GD2 immunotherapy. The 3‐year overall survival (OS) and event‐free survival (EFS) for the entire cohort was 60% (54.1%–66.5%) and 50.2% (44.4%–56.7%), respectively. Risk factors for poor EFS included age ( p < 0.001), INRG risk group ( p < 0.001), MYCN amplification ( p < 0.001), ferritin levels ( p = 0.04), and lactate dehydrogenase levels ( p < 0.001).
Conclusions
Lack of accurate diagnostic risk stratification may contribute to poor outcomes of patients with NB in India. Sub‐optimal outcomes are primarily seen in HR‐NB, with limited access to HDCT/ASCR and anti‐GD2 immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- St. John's Medical College Hospital, Bengaluru, India.
- MVR Cancer Centre and Research Institute, Kozhikode, India.
- Basavatarakam Indo American Cancer Hospital, Hyderabad, India.
- Max Super Specialty Hospital, New Delhi, India.
- Tata Medical Center, Kolkata, India.
- Sher-i-Kashmir Institute of Medical Sciences, Srinagar, India.
Zitieren
APA
Reddy, J. M., Krishnan, Y., Patil, V., Arora, R. S., Bhattacharya, A., Guru, F., Kakkar, S., Kalra, M., Mahajan, A., Mudaliar, S., Radhakrishnan, V., Raj, R., Rani, S., Patel, N., Modak, S., & Kanwar, V. S. (2026). Treatment and Outcome of Children With Neuroblastoma in India: Report From the InPOG‐NB‐18‐01 India Neuroblastoma Registration Study. Pediatric Blood & Cancer. https://doi.org/10.1002/1545-5017.70431
Vancouver
Reddy JM, Krishnan Y, Patil V, Arora RS, Bhattacharya A, Guru F, et al. Treatment and Outcome of Children With Neuroblastoma in India: Report From the InPOG‐NB‐18‐01 India Neuroblastoma Registration Study. Pediatric Blood & Cancer. 2026. doi:10.1002/1545-5017.70431
BibTeX
@article{Reddy2026,
author = {Reddy, Jyothi Muni and Krishnan, Yamini and Patil, Veerendra and Arora, Ramandeep Singh and Bhattacharya, Arpita and Guru, Faisal and Kakkar, Shruti and Kalra, Manas and Mahajan, Amita and Mudaliar, Sangeetha and Radhakrishnan, Venkataraman and Raj, Revathi and Rani, Sirisha and Patel, Nikita and Modak, Shakeel and Kanwar, Vikramjit S},
title = {Treatment and Outcome of Children With Neuroblastoma in India: Report From the InPOG‐NB‐18‐01 India Neuroblastoma Registration Study},
journal = {Pediatric Blood & Cancer},
year = {2026},
doi = {10.1002/1545-5017.70431}
}
EUVIMED